Pirfenidone PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified Pirfenidone PCD pharma franchise company offering 3 Pirfenidone formulations across Tablets. Every batch is manufactured in DCGI-approved, WHO-GMP compliant facilities and supplied to franchise partners on a monopoly basis with full promotional backing.
What is Pirfenidone?
Pirfenidone is an orally administered antifibrotic and anti-inflammatory agent. It reduces fibroblast proliferation and collagen deposition, and downregulates profibrotic mediators such as transforming growth factor-beta (TGF-beta) and tumour necrosis factor-alpha. It is approved for the treatment of idiopathic pulmonary fibrosis (IPF), where it slows the rate of decline in lung function. It is a specialist prescription-only medicine requiring liver function monitoring. See the compound record on PubChem.
Pirfenidone Range Available for Franchise
Our Pirfenidone portfolio comprises 3 formulations available in the following dosage forms: Tablets. Brand names, compositions, packing and net rates are shared on request with partners holding a valid Drug License. Contact us for the current Pirfenidone price list and stock position.
Therapeutic Applications of Pirfenidone
Pirfenidone is indicated for idiopathic pulmonary fibrosis and is also used in progressive fibrosing interstitial lung disease under specialist judgement. Prescriptions are written almost exclusively by pulmonologists and respiratory medicine specialists, with input from rheumatologists in connective-tissue-disease-associated ILD and from chest physicians at tertiary centres.
Why Pirfenidone is a High-Potential Molecule for Distributors
Pirfenidone is a specialty molecule, and its economics are the opposite of a mass-market product: low patient counts, but very high value per patient and near-total adherence, because IPF therapy is lifelong and stopping is not an option for the patient. Awareness and diagnosis of interstitial lung disease in India have risen sharply following the expansion of HRCT access and post-COVID pulmonary follow-up, which has enlarged the diagnosed IPF pool considerably. For a distributor with pulmonology coverage, a small number of patients generates disproportionate monthly revenue, and competition at the chemist level is minimal because the product is dispensed on specialist referral rather than walk-in demand.
Why Choose Cafoli Lifecare for Your Pirfenidone Franchise
Cafoli Lifecare works with over 1000+ franchise partners across India. Partners receive monopoly rights for their district or territory, WHO-GMP certified and DCGI-approved products, complete promotional inputs (visual aids, MR bags, samples, prescription pads, gifts), transparent net rates, and dependable dispatch. Our documentation and stock support are built for distributors who want to scale without operational friction.
References
- PubChem — Pirfenidone compound record (NIH / NCBI)
- MedlinePlus — Pirfenidone drug information (US National Library of Medicine)
- PubMed — clinical literature on Pirfenidone
Our formulations of Pirfenidone find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: